PYPDHealthcare · BiotechnologyThe 4 Wall Street analysts covering PolyPid Ltd. hold a median 12-month price target of $13 — +150.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores PolyPid Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (93): The share count has been shrinking and the company is not leaning on new borrowing.
Quality (16): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PYPD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +150.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $13 |
| 11 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | $13 |
| 13 Nov 2025 | Roth Capital | Maintains | Buy | — |
| 14 Aug 2025 | Craig-Hallum | Maintains | Buy | — |
| 13 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 June 2025 | Roth Capital | Maintains | Buy | — |
| 17 June 2025 | JMP Securities | Maintains | Market Outperform | — |
| 9 June 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 June 2025 | Roth Capital | Initiates | Buy | — |
| 2 June 2025 | HC Wainwright & Co. | Assumes | Buy | $11 |
| 14 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 Dec 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 16 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Nov 2024 | Craig-Hallum | Initiates | Buy | — |
| 2 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PYPD appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Aug 2026, PolyPid Ltd. returned +42.4% against +19.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 86% of US stocks
Cheaper than 6% of US stocks
Cheaper than 75% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 6% of US stocks
Higher than 5% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
PolyPid Ltd. has a market value of $103.6M and an enterprise value of $98.6M.
Revenue in the twelve months to 31 Mar 2026: $0.0.
Net income over the same four quarters: −$33.6M.
Diluted earnings per share, trailing twelve months: $−1.91.
Trailing P/E: −2.4×; forward P/E: −4.2× — the forward figure prices analyst consensus estimates, not reported earnings.
PolyPid Ltd. employs 69 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own PolyPid Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published the Q2 2026 earnings call transcript for PolyPid Ltd. (PYPD). The item provides the transcript of the company's second-quarter 2026 earnings call.
Why it matters — PYPD watchers can review the earnings call transcript for management's discussion of the company's Q2 2026 performance and outlook.
PolyPid reported that the FDA accepted its new drug application for D-PLEX100, and it reached a commercialization agreement with Azurity Pharmaceuticals for the U.S. and Canadian markets.
Why it matters — A PYPD watcher would care because regulatory acceptance and a commercialization deal are key milestones that move D-PLEX100 closer to market entry.
PolyPid provided a corporate update and reported second quarter 2026 financial results. The FDA accepted the D-PLEX100 New Drug Application with Priority Review, setting a PDUFA goal date of November 28, 2026, approximately one quarter ahead of previously communicated guidance.
Why it matters — This news signals progress toward potential U.S. approval of D-PLEX100, with a review timeline earlier than previously guided, which is significant for PolyPid watchers following the product's regulatory path.
PolyPid Ltd. announced it will report its second quarter 2026 financial results and operational highlights before U.S. markets open on August 12, 2026, and will hold a conference call and webcast at 8:30 AM ET that day to discuss the results and business operations.
Why it matters — The announcement provides the date and time for PolyPid's quarterly update, which will include financial results and an operational overview that shareholders and analysts will be watching.
PolyPid announced that the U.S. FDA has accepted its New Drug Application (NDA) for D-PLEX₁₀₀ and granted Priority Review, with a PDUFA target action date of November 28, 2026 — roughly one quarter ahead of the company's prior guidance.
Why it matters — FDA acceptance with Priority Review moves D-PLEX₁₀₀ a step closer to potential U.S. approval, and the faster-than-expected review timeline could shorten the wait for a regulatory decision.
The 4 Wall Street analysts covering PolyPid Ltd. have a median 12-month price target of $13, with estimates ranging from $8 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering PolyPid Ltd., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks PolyPid Ltd. 50 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, PolyPid Ltd. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (93 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +150.8% from the last close, and Ticker Nerd's factor model ranks PolyPid Ltd. 50 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering PolyPid Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PYPD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $14 over the next 12 months.
PolyPid Ltd. returned +42.4% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
PolyPid Ltd. is an innovative biopharmaceutical company developing long-acting, controlled-release medicines that deliver therapy precisely at the site of care.
The most recent item we track (Seeking Alpha, 12 Aug 2026): "PolyPid Ltd. (PYPD) Q2 2026 Earnings Call Transcript". Seeking Alpha published the Q2 2026 earnings call transcript for PolyPid Ltd. (PYPD). The item provides the transcript of the company's second-quarter 2026 earnings call.
PolyPid Ltd. is an innovative biopharmaceutical company developing long-acting, controlled-release medicines that deliver therapy precisely at the site of care. It specializes in locally administered therapeutics using its proprietary PLEX (Polymer-Lipid Encapsulation matriX) and Kynatrix technologies, which enable precise, localized drug delivery at predetermined rates over days to months. The lead product candidate, D-PLEX100, provides prolonged antibiotic exposure directly at surgical sites to prevent surgical site infections, particularly in abdominal colorectal surgeries. PolyPid Ltd. also advances applications of its platform in oncology, obesity, diabetes, and other high-impact indications, including a long-acting GLP-1 receptor agonist delivery system. The company maintains a GMP-certified manufacturing facility supporting commercial-scale production. Founded in 2008 and headquartered in Petah Tikva, Israel, PolyPid Ltd. focuses on improving patient outcomes in surgical care, metabolic diseases, and beyond through targeted precision drug delivery.
CEO Ms. Dikla Czaczkes Akselbrad · 69 employees · Israel · https://www.polypid.com
